HUMA - Humacyte, Inc.

QQQ $ 474.46 $ -5.47 (-1.14 %)

DIA $ 412.48 $ 0.89 (0.22 %)

SPY $ 560.78 $ -1.35 (-0.24 %)

TLT $ 98.13 $ -0.26 (-0.26 %)

GLD $ 232.75 $ 0.73 (0.31 %)

Previous Close

$ 7.05

Open

$ 7.11

Bid

$ 7.05 x 500

Ask

-- x --

Day's Range

$ 6.95 - $ 7.47

52 Week Range

$ 1.96 - $ 9.97

Volume

2,084,455

Average Volume

Market Cap

839.04M

Beta (5Y Monthly)

$ 1.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-13-2024	03-31-2024	10-Q
3	03-28-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	05-12-2023	03-31-2023	10-Q
7	03-24-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-12-2022	06-30-2022	10-Q
10	05-13-2022	03-31-2022	10-Q
11	03-29-2022	12-31-2021	10-K
12	11-15-2021	09-30-2021	10-Q
13	08-16-2021	06-30-2021	10-Q
14	05-17-2021	03-31-2021	10-Q
15	02-16-2021	12-31-2020	10-K
16	11-13-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

How Is The Market Feeling About Humacyte?
08/19/2024 14:00:17

Benchmark Reiterates Buy on Humacyte, Main...
08/14/2024 14:16:24

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

Humacyte Q2 2024 GAAP EPS $(0.48) Misses $...
08/13/2024 11:02:51

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.24) by...

unpacking-the-latest-options-trading-trends-in-humacyte

Unpacking the Latest Options Trading Trend...
08/12/2024 19:01:04

Benchmark Reiterates Buy on Humacyte, Main...
08/12/2024 17:00:21

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

delay-hits-humacytes-bioengineered-human-tissue-implant-for-vascular-trauma-injuries-fda-extends-time-to-review

Delay Hits Humacyte's Bioengineered Human ...
08/12/2024 13:21:49

FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular...

why-ainos-shares-are-trading-higher-by-around-38-here-are-20-stocks-moving-premarket

Why Ainos Shares Are Trading Higher By Aro...
08/12/2024 10:04:36

Humacyte Says The FDA Will Require Additio...
08/09/2024 20:09:52

8-best-performing-small-caps-in-july-find-out-which-stock-jumped-803

8 Best-Performing Small Caps In July: Find...
08/01/2024 20:54:40

Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 ...

Humacyte Announced Topline Results From V0...
07/31/2024 11:16:52

whats-going-on-with-huamacyte-shares-tuesday

What's Going On With Huamacyte Shares Tues...
07/16/2024 18:48:00

Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement wit...

why-solaredge-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-mondays-mid-day-session

Why SolarEdge Shares Are Trading Lower By ...
07/15/2024 17:23:20

BTIG Maintains Buy on Humacyte, Raises Pri...
07/15/2024 17:03:43

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $8 to $11.

microstrategy-coinbase-robinhood-tesla-and-other-big-stocks-moving-higher-on-monday

MicroStrategy, Coinbase, Robinhood, Tesla ...
07/15/2024 15:04:09

(HUMA) - Analyzing Humacyte's Short Interest
07/15/2024 13:00:15

Pluristyx Announces License Agreement with...
07/09/2024 14:07:51

Partnership Includes Access to panCELLa™ Platform for Generating Hypoimmune Cells for Clinical Implantation

Cantor Fitzgerald Reiterates Overweight on...
07/02/2024 14:43:42

Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte (NASDAQ:HUMA) with a Overweight and maintains $7 price target.

Benchmark Reiterates Buy on Humacyte, Main...
07/02/2024 13:27:50

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

Humacyte shares are continuing higher afte...
07/02/2024 11:11:54

why-humacyte-stock-is-trading-15-higher-monday

Why Humacyte Stock Is Trading 15% Higher M...
07/01/2024 17:39:45

Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular ...